Clinical trials: Left Heart Failure
Heart Failure, Tachyarrhythmia
Iperia/Sentus QP Study
The objective of this study is to confirm the safety and efficacy of the new Sentus OTW QP LV lead and Iperia ICD family. The study focuses on the safety and efficacy of the QP device system.
- Trial name
- NCT02181686
- Where
- 24 sites in Austria, Denmark and 9 more
- Volunteers
- 152 people
- Sponsor
- Biotronik SE & Co. KG
Heart Failure (HF)
Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients
The primary objective of this study is to demonstrate that in patients with recuperated/normalized left ventricular function, defined as an ejection fraction (EF) ≥ 50%, after implantation of cardiac resynchronization therapy…
- Trial name
- STOP-CRT (NCT02200822)
- Testing
- beta blockers, RAAS blockers
- Where
- Belgium
- Volunteers
- 80 people
- Sponsor
- Hasselt University
Obstructive Sleep Apnea, Pulmonary Edema Cardiac Cause
Obstructive Sleep Apnea Treatment on Cardiovascular Events in Patients With Acute Cardiogenic Pulmonary Edema: CPAP-CARE STUDY.
Despite the advances in the treatment of acute cardiogenic pulmonary edema (ACPE), the readmissions rates and cardiovascular events remain very high.
- Trial name
- CPAP-CARE (NCT03936751)
- Testing
- CPAP, Nasal Strips
- Where
- 4 sites in Brazil
- Volunteers
- 150 people
- Sponsor
- University of Sao Paulo
Chronic Heart Failure
LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart failure and preserved left-ventricular ejection…
- Trial name
- NCT00887588
- Testing
- LCZ696, Valsartan
- Where
- 81 sites in United States, Argentina and 12 more
- Volunteers
- 307 people
- Sponsor
- Novartis Pharmaceuticals
Left Ventricular Ejection Fraction Less Then or Equal to 50percent
Left Bundle Branch Area Pacing in Heart Failure Patients With Ejection Fraction Below Normal
While cardiac resynchronization therapy remains the mainstay for advanced HF, it is not always feasible due to unfavorable anatomy of coronary sinus or pacing characteristics.
- Trial name
- NCT06148571
- Testing
- left bundle branch area pacing
- Where
- South Korea
- Volunteers
- 142 people
- Sponsor
- Seoul National University Hospital
Heart Failure
Clinical Prospective ranDomized Trial to Evaluate the Non-inferiority of Left Bundle Branch Area Pacing Vs Cardiac ResynchronIzatioN Therapy With ECG guIded AV Optimization
Cardiac resynchronization therapy is the gold standard therapy for patients with advanced HF left ventricle dysfunction and large QRS.
- Trial name
- DA VINCI (NCT07107048)
- Testing
- Pacemaker and defibrillator
- Where
- Italy
- Volunteers
- 194 people
- Sponsor
- Leonardo Calò, MD
Congestive Heart Failure
Study of Coronary Artery Disease by Two Types of Angiography
The purpose of this study is to test the ability of a new X-ray technique called CT angiography to identify significant narrowing of the coronary arteries compared to traditional coronary angiogram.
- Trial name
- NCT00273819
- Testing
- CT angiography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VA Connecticut Healthcare System
Heart Failure
Biomarkers and Therapeutic Modelisation in Heart Failure
The telemonitoring systems for congestive HF did not yet prove their efficacy despite initial encouraging results. Decongestion is one of the main objectives in Congestive HF, but an appropriate titration of diuretics is…
- Trial name
- BIOMIC (NCT01655134)
- Testing
- Blood simples, Capillary punction, Urine simples
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Central Hospital, Nancy, France
Heart Failure
Placement of CS/LV Pacing Leads With EnSite NavX Guidance
This study utilizes the 3D mapping capabilities of the EnSite NavX mapping system to help guide the placement of the left ventricular lead during cardiovascular resynchronization therapy implant procedures with the goal of…
- Trial name
- NCT00577187
- Testing
- EnSite NavX-Guided CRT implant
- Where
- United States
- Sponsor
- Abbott Medical Devices
Heart Failure
A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System
The objective of this study is to evaluate the safety and performance of the V-LAP System in subjects with New York Heart Association (NYHA) functional class II and III HF, irrespective of left ventricular ejection fraction.
- Trial name
- NCT06147336
- Testing
- V-LAP™ SYSTEM
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vectorious Medical Technologies Ltd.
Mitral Valve Regurgitation, Left Ventricular Dysfunction
VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study
The purpose of this prospective, non-randomized, single-arm feasibility study is to evaluate safety and feasibility of the iCoapsys System in patients with functional mitral valve insufficiency caused by annular dilation and/or…
- Conditions
- Mitral Valve Regurgitation, Left Ventricular Dysfunction, Heart Failure, Mitral Insufficiency
- Trial name
- VIVID (NCT00512005)
- Testing
- Percutaneous mitral valve repair
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Myocor
Symptomatic Congestive Heart Failure
The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF
The goal of this observational cohort study, which is both retrospective and prospective, is to evaluate the long-term clinical and instrumental response to Cardiac Contractility Modulation (CCM) treatment in adult subjects…
- Trial name
- PREDICT-CCM (NCT06973902)
- Testing
- Cardiac Contractility Modulation (CCM) implant
- Where
- 13 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Quovadis Associazione
Heart Failure
Biventricular Versus Right Ventricular Pacing
The study is a randomized, single-blind crossover prospective study in which investigators will determine the clinical outcomes of cardiac resynchronization therapy (CRT) pacing modalities in patients with left ventricular assist…
- Trial name
- NCT06298669
- Testing
- Biventricular Pacing, Right Ventricular Pacing
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Indiana University
Heart Failure
Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices
Heart failure remains a major cause of morbidity and mortality. Many patients with heart failure receive support from a left ventricular assist device (LVAD) at some point in the course of their disease.
- Trial name
- NCT02547766
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Utah
Renal Failure, Left Ventricular Hypertrophy
Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
The primary objective is to determine if the use of losartan, an angiotensin II receptor blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive effects, in patients with near end stage chronic…
- Trial name
- NCT00602004
- Testing
- losartan
- Where
- Australia
- Volunteers
- 52 people
- Sponsor
- Melbourne Health
Heart Failure
AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure
To determine the safety and efficacy of an intracoronary injection of adenovirus 5 encoding human adenylyl cyclase 6 (RT-100) in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) in a Phase 3…
- Trial name
- FLOURISH (NCT03360448)
- Testing
- Ad5.hAC6
- Sponsor
- Renova Therapeutics
End-stage Heart Failure
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
This study is to evaluate the safety and effectiveness of the Corheart 6 Left Ventricular Assist System (Corheart 6 LVAS) used for the treatment of end-stage heart failure.
- Trial name
- NCT05353816
- Testing
- Corheart 6 Left Ventricular Assist System
- Where
- 11 sites in China
- Volunteers
- 50 people
- Sponsor
- Shenzhen Core Medical Technology CO.,LTD.
Chronic Heart Failure With Reduced Ejection Fraction, Worsening Heart Failure
A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction (HFrEF). HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body…
- Trial name
- NCT05658458
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- 12 sites in India
- Volunteers
- 205 people
- Sponsor
- Bayer
Heart Failure
Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
The purpose for this study (CY 1124) is to evaluate the effects of CK-1827452, a cardiac myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and myocardial efficiency in patients with heart…
- Trial name
- NCT00748579
- Testing
- CK-1827452
- Where
- 3 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Cytokinetics
Heart Failure
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these…
- Trial name
- PROVE-HF (NCT02887183)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 77 sites in United States
- Volunteers
- 794 people
- Sponsor
- Novartis Pharmaceuticals